Humana (NYSE:HUM – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat reports. They presently have a $253.00 price objective on the insurance provider’s stock, down from their previous price objective of $519.00. Jefferies Financial Group’s price objective would indicate a potential upside of 4.03% from the company’s previous close.
Other analysts have also issued research reports about the company. Oppenheimer decreased their price objective on Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Royal Bank of Canada upped their target price on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. TD Cowen raised their price target on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft dropped their price target on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Finally, Truist Financial increased their price objective on shares of Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research report on Monday, July 15th. One analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $324.86.
Check Out Our Latest Stock Report on HUM
Humana Stock Performance
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the firm earned $8.94 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Research analysts expect that Humana will post 16.01 EPS for the current fiscal year.
Institutional Trading of Humana
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pzena Investment Management LLC boosted its position in Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after purchasing an additional 1,955,375 shares in the last quarter. Davis Selected Advisers increased its holdings in shares of Humana by 16.1% during the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after purchasing an additional 321,233 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Humana by 118.9% in the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares during the period. Legal & General Group Plc boosted its holdings in Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock worth $442,396,000 after buying an additional 24,842 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board grew its position in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after buying an additional 1,050,459 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- What is the Australian Securities Exchange (ASX)
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What Investors Need to Know to Beat the Market
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What is a Bond Market Holiday? How to Invest and Trade
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.